What are you looking for?

Reimagining Ocular Drug Delivery Leveraging innovative nanotechnology and
drug delivery systems to better treat eye conditions
Learn more about us
OptX Glaucoma Contact Lenses Delivery of latanoprost and timolol from micelles-based lenses Learn more about our technology Our First Step

Main Site

The Solution

Optimal Drug Delivery

OptX Glaucoma deploys delivery of latanoprost and timolol from micelles-based contact lenses (MCLs) for the treatment of Glaucoma.

Simultaneous application of latanoprost (increases outflow of aqueous humor) and timolol (inhibits production of aqueous humor) allows for revolutionary IOP reduction.

Net Cost Savings

In a multiple studies, using a beginner-stage version of our solution and conventional eye drops, it is seen that the IOP reduced by our solution goes from 45 to 25 percent reduction at one 5 day usage, while eye drops go from 40 to 5 percent reduction in the same time frame.

With comparable price, OptX Glaucoma is providing better clinical outcomes.

Novel Biodegradation

OptX Glaucoma thrives on patient adherence, and doesn’t require a strict regimen like those seen with eye drops. Contact lenses can be placed for 4 or 5 days, after which the lenses would have dissolved.

These lenses are based on nanowafer technology which leverages a PLGA backbone w/ micelle nanoparticles and relies on an anvironmentally and biologically sustainable process.

Innovation that Heals

Our First Priority - Treating Chronic Glaucoma

Glaucoma affects about 60.5 million people, leaving 8.2 million with bilateral blindness.

  • It is in fact the second largest cause of blindness in the world after cataracts
  • Glaucoma leads to elevated intraocular pressure (IOP) in the eye and degeneration of the axons of retinal ganglion cells (RGCs), which leads to loss of vision and potentially to blindness if not treated

Growing Glaucoma

Glaucoma market size was USD 6.59 billion in 2019 and is projected to reach USD 11.05 billion by 2027, exhibiting a CAGR of 6.1% during the forecast period.

More than 60 million people around the world have gluacoma, and 90% are on an eye drop treatment plan.

Contact Lenses
On the Rise

There are about 38 million contact lens wearers in the United States and approximately 125 million wearers worldwide, and the worldwide contact lens market is estimating at $6.8 billion.

The U.S. market is estimated at $2.6 billion in 2011.

Our Initial Product
OptX Glaucoma - Biodegradable Contact Lenses for Glaucoma Patients

Leveraging cutting-edge ocular drug delivery